Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/13588
Title: Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
Authors: D. A. Reardon
J. E. Herndon
K. B. Peters
A. Desjardins
A. Coan
E. Lou
A. L. Sumrall
S. Turner
E. S. Lipp
S. Sathornsumetee
J. N. Rich
J. H. Sampson
A. H. Friedman
S. T. Boulton
D. D. Bigner
H. S. Friedman
J. J. Vredenburgh
Duke University School of Medicine
Mahidol University
Cleveland Clinic Foundation
Keywords: Biochemistry, Genetics and Molecular Biology;Medicine
Issue Date: 23-Oct-2012
Citation: British Journal of Cancer. Vol.107, No.9 (2012), 1481-1487
Abstract: Background: Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial bevacizumab progression is poor. We evaluated bevacizumab continuation beyond initial progression among recurrent glioblastoma patients as it is a common, yet unsupported practice in some countries. Methods: We analysed outcome among all patients (n99) who received subsequent therapy after progression on one of five consecutive, single-arm, phase II clinical trials evaluating bevacizumab regimens for recurrent glioblastoma. Of note, the five trials contained similar eligibility, treatment and assessment criteria, and achieved comparable outcome. Results: The median overall survival (OS) and OS at 6 months for patients who continued bevacizumab therapy (n55) were 5.9 months (95% confidence interval (CI): 4.4, 7.6) and 49.2% (95% CI: 35.2, 61.8), compared with 4.0 months (95% CI: 2.1, 5.4) and 29.5% (95% CI: 17.0, 43.2) for patients treated with a non-bevacizumab regimen (n44; P0.014). Bevacizumab continuation was an independent predictor of improved OS (hazard ratio0.64; P0.04). Conclusion: The results of our retrospective pooled analysis suggest that bevacizumab continuation beyond initial progression modestly improves survival compared with available non-bevacizumab therapy for recurrent glioblastoma patients require evaluation in an appropriately randomised, prospective trial. © 2012 Cancer Research UK All rights reserved.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84867900118&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/13588
ISSN: 15321827
00070920
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.